Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063754 | 0.87 | KCNH2 (0.47) | ALDH1A1PKMHPGDKCNH2PI4KA | |
| SCHEMBL9817100 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL28413083 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL27668867 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL4445935 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL10697416 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL27699983 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL9133514 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL730079 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL28300118 | 0.85 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| EP-1322309-B1 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-6884815-B1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1322309-A4 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1322309-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002049993-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | ALDH1A1 4042/4885PKM 4470/4885HPGD 2949/4885 |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | ALDH1A1 3370/4885PKM 3793/4885HPGD 1577/4885 |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | ALDH1A1 149/4885PKM 215/4885HPGD 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.